Introduction
Magnetic iron oxide nanoparticles with superparamagnetic properties and modified surfaces have been tested in various in vivo applications, including magnetic resonance imaging, tissue repair, immunoassays, detoxification, hyperthermia, and drug delivery. 1, 2 Magnetic iron oxide nanoparticles with high magnetization, small particle size, and a narrow particle size distribution are very important in the biomedical and bioengineering fields for achieving uniform physical and chemical properties. 3 Iron oxide nanoparticles with small particle sizes have been shown to have antimicrobial properties 4 that depend on three factors, ie, size, stability, and concentration in the growth medium. However, magnetic iron oxide nanoparticles suffer from agglomeration during preparation, which decreases their efficacy in terms of inhibiting bacterial growth. Therefore, such particle surfaces need to be coated with nontoxic and biocompatible polymers to avoid agglomeration. Chitosan has been widely used as a nanoparticle coating material because it is nontoxic, biodegradable, biocompatible, and has intrinsic antimicrobial properties. 5, 6 Furthermore, silver nanoparticles, including silver-coated magnetic nanoparticles, were recently developed as promising antimicrobial magnetic based-nanoparticles.
Streptomycin was widely used until widespread emergence of bacterial resistance limited its clinical usefulness. The mechanism of microbial resistance to streptomycin has been reviewed extensively elsewhere. 12 Several efforts were made to restore the usefulness of streptomycin and other aminoglycosides by chemical modification to develop new generations of aminoglycosides that bypass existing multidrug bacterial resistance pathways and reduce the concerns about their toxicity, in particular ototoxicity and nephrotoxicity. 13 Despite their limitations, including bacterial resistance, poor oral pharmacokinetics, clinical toxicity, and side effects, aminoglycosides (including the prototype streptomycin) remain clinically significant antimicrobial agents in the treatment of a broad range of bacterial infections. 13, 14 In the present study, for the first time, we report on novel streptomycin-loaded chitosan-magnetic iron oxide nanoparticles (Strep-CS-MNP) and investigate their controlled release and antimicrobial activity in vitro. The latter was determined using a pathogenic strain of methicillin-resistant Staphylococcus aureus (MRSA), a microorganism causing serious infection and of considerable public health and clinical significance.
Materials and methods Materials
Ferric chloride hexahydrate (FeCl 3 ⋅ 6H 2 O) (99%) and ferrous chloride tetrahydrate (FeCl 2 ⋅ 4H 2 O) (.99%) were obtained from Merck KGaA (Darmstadt, Germany). Chitosan (low molecular weight, deacetylation 75%-85%) was purchased from Sigma-Aldrich (Saint Louis, MO, USA). Acetic acid (99.8%) was sourced from Hamburg Industries Inc (Hamburg, Germany). Streptomycin sulfate was obtained from Sigma-Aldrich. All aqueous solutions were prepared with deionized water. in solution was added slowly to a 2 M NaOH solution while stirring, with the pH kept at less than 10 at room temperature. The solution was sonicated for a further 60 minutes at room temperature. The particles were filtered, washed three times with deionized water, and dried.
Preparation of iron oxide nanoparticles

Preparation of cs-MNP
Chitosan (2.0 g) was dissolved in a 1% acetic acid solution.
The chitosan solution and Fe 3 O 4 were mixed together in a flask, and the mixture was stirred for 18 hours. Chitosan-coated magnetic nanoparticles (CS-MNP) were separated using a permanent magnet and dried at 70°C for 2 hours.
Preparation of strep-cs-MNP
Streptomycin was loaded onto CS-MNP using a method similar to that reported previously. 15 Briefly, a streptomycin solution (0.58 g) was added dropwise while stirring into an aqueous dispersion of MNP. The mixture of CS-MNP in the streptomycin solution was magnetically stirred at room temperature for 18 hours to facilitate streptomycin uptake. The product, ie, Strep-CS-MNP, was separated using a permanent magnet.
loading and release of streptomycin from strep-cs-MNP
To measure the amount of streptomycin loaded on the CS-MNP, 5 mg of the nanocomposite was weighed accurately and dissolved in concentrated HCl/HNO 3 , ie, conditions that would completely dissolve this nanocomposite and release 100% of the streptomycin content. Next, the amount of streptomycin released was measured by ultraviolet-visible spectroscopy using streptomycin absorbance at 200 nm and calibration curves.
In order to determine the percentage release and drug release kinetics, 85 mg of each nanocomposite was suspended into 250 mL of phosphate-buffered saline at pH 7.4. A quantity of medium solution (3 mL) was removed for analysis at given time intervals and replaced with 3 mL of the same buffered solution. The cumulative amount of streptomycin released into the solution was measured at different time intervals using an ultraviolet-visible spectrophotometer at 200 nm.
characterization of strep-cs-MNP nanocomposite
The magnetic nanoparticles and nanocomposite were characterized by Fourier transform infrared (FTIR) spectroscopy, X-ray diffraction, thermogravimetric analysis, and magnetization measurements. The FTIR spectra were recorded over the range of 400-4,000 cm −1 on a Thermo Nicolet Nexus, Smart Orbit spectrometer using the KBr disk method. X-ray diffraction spectra were obtained in the range of 20-70 degrees using an XRD-6000 diffractometer International Journal of Nanomedicine 2014:9 submit your manuscript | www.dovepress.com
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Novel streptomycin-chitosan-magnetic nanoantibiotic (Shimadzu, Tokyo, Japan) with CuK α radiation (λ 1.5406 Å) at 30 kV and 30 mA. Thermogravimetric analysis was carried out using a Metter-Toledo 851e instrument (Greifensee, Switzerland) with a heating rate of 10°C per minute in 150 µL alumina crucibles and in the range of 30°C-900°C. A scanning electron microscope (Nova™ NanoSEM 230; FEI, Hillsboro, OR, USA) was used to observe the surface morphology of the samples. Magnetic properties were evaluated using a 7404 vibrating sample magnetometer Lake Shore Cryotronics Inc (Westerville, OH, USA). Ultravioletvisible spectra were measured to determine the controlled release which was performed using an ultraviolet-visible spectrophotometer (Perkin Elmer, Waltham, MA, USA).
antimicrobial activity of strep-cs-MNP against Mrsa
A bacterial strain of methicillin-resistant Staphylococcus aureus (MRSA), a human pathogen of clinical significance and causing a range of minor to life-threatening infections of the skin, respiratory tract, and urinary tract, as well as septicemia, was obtained from the Microbial Culture Collection Unit, Institute of Bioscience, Universiti Putra Malaysia for use in the present study. MRSA cultures were maintained on Luria-Bertani agar (Fluka, Buchs, Switzerland). Prior to incubation with the novel nanoparticles, the bacteria were cultured overnight in 5 mL of Luria-Bertani broth in a Certomat BS-T incubation shaker (Sartorius Stedim Biotech, Aubagne, France) at 37°C and 150 rpm until the culture reached an OD 600 of 1.0 (Spekol UV VIS 3.02, Analytik Jena, Jena, Germany) corresponding to 10 9 colony-forming units per mL. The overnight cultures were diluted to 10 8 colonyforming units per mL using sterile Luria-Bertani broth.
The antimicrobial activity of free streptomycin and the synthesized streptomycin nanocomposite was evaluated against MRSA using the agar diffusion (disk and cup) method as reported elsewhere. 16 Briefly, 20 mL of liquid Mueller Hinton agar (pH 7.3±0.2 at 25°C) was poured onto disposable sterilized Petri dishes and allowed to solidify. The surface of the solidified agar plates were allowed to dry in an incubator prior to streaking of microorganisms onto the surface of the agar plates. Next, 100 µL of the microbial culture suspension in broth containing approximately 10 6 colony-forming units per mL as measured spectrophotometrically was streaked over the dried surface of the agar plate, spread uniformly using sterilized glass rods, and allowed to dry before applying the loaded disks. The Strep-CS-MNP was suspended in sterilized distilled water, and blank sterilized Whatman No 1 filter paper disks were loaded with the suspension. The loaded disks were applied carefully onto the surface of the seeded agar plates using sterile forceps. In addition, two wells were made in the agar using a sterilized cork borer and the two wells were filled with the nanoparticle suspensions and the control, respectively. The experiment was carried out in triplicate and the diameters of the zones of inhibition were measured after 24 hours of incubation at 37°C. Free streptomycin was used as a control.
Results and discussion X-ray diffraction any iron products such as hematite (α-Fe 2 O 3 ), goethite, or iron hydroxides.
The average particle size was calculated using the DebyeScherrer formula, as shown in equation (1):
where D is the mean grain size, k is the Scherrer constant (0.89), λ is the wavelength of X-ray diffraction (0.15418 nm), θ is the Bragg diffraction angle in degrees, and β is the full width at half maximum intensity in radians. The diffraction peak corresponding to the lattice plane (311) at 2θ=35.4° was used for calculation because this peak is well resolved and does not show any interferences. By substituting the full width at half maximum of the main peak (311), average particle sizes were calculated as 40 nm, 24 nm, and 16 nm for the magnetic nanoparticles, CS-MNP, and Strep-CS-MNP, respectively.
Infrared spectroscopy
Figure 2A-D shows FTIR spectra for the magnetic nanoparticles, CS-MNP, Strep-CS-MNP, and free streptomycin, respectively. In Figure 2A , the magnetic nanoparticles show an absorption peak at 536 cm −1 which is due to Fe-O stretching in Fe 3 O 4 . However, the CS-MNP and Strep-CS-MNP samples show characteristic Fe-O peaks at 541 and 542 cm -1 , respectively, confirming the presence of magnetite nanoparticles in both samples.
Comparing the spectrum of CS-Fe 3 O 4 ( Figure 2B ) with the spectrum of the Fe 3 O 4 nanoparticles (Figure 2A 
, that are due to NH 3 +17 and glycosidic bond stretching vibrations, 18, 19 respectively. These bands confirm coating of the magnetic nanoparticle with the chitosan polymer. The streptomycin molecule showed absorption bands at 1,629, 1,454, and 1,034 cm −1 ( Figure 2D ). These bands are present in the spectra of Strep-CS-MNP nanocomposite with a slight shift, showing that the drug was incorporated into the nanocomposite ( Figure 2C) . Figure 3 shows the interaction between streptomycin, chitosan, and magnetic nanoparticles in the Strep-CS-MNP nanocomposite. Using FTIR data, the chitosan polymer and the magnetic nanoparticles interacted via glycosidic bonds (MNP-O-CS). Dissolving the chitosan in acetic acid enabled a protonated NH 2 group to form NH 3 + . Therefore, streptomycin with -OH or -NH 2 groups bound with chitosan via hydrogen bonds. Figure 4A) shows that the weight loss from the magnetic nanoparticles in the temperature range of 30°C-850°C is about 5.8%. This weight loss was due to removal of absorbed water in the sample as well as removal of surface hydroxyl groups. [20] [21] [22] The thermogravimetric analysis curve for CS-MNP ( Figure 4B ) shows a total weight loss of 7.7%. The increasing weight loss of the CS-MNP compared with that for the magnetic nanoparticles indicate binding of chitosan to the magnetic nanoparticles, with a 2.0% chitosan content. Figure 4C shows the thermogravimetric analysis curve for Strep-CS-MNP. Weight loss below 200°C was due to removal of physically and chemically absorbed water. Strep-CS-MNP began to decompose at about 200°C, and the temperature of the final decomposition was around 800°C (Figure 4 inset), with a total weight loss of 12.2%. The weight loss from CS-MNP was less than that from Strep-CS-MNP, which confirmed loading of streptomycin onto the CS-MNP surface.
Measurement of magnetic properties
The magnetic properties of the magnetic nanoparticles and Strep-CS-MNP are shown in Figure 5A -B, respectively. The study recorded magnetization (M s ) values against an applied magnetic field (O e ) at room temperature using a vibrating sample magnetometer. The curves exhibited negligible coercivity or remanent magnetization due to the superparamagnetic properties of the magnetic nanoparticles. 23 This property is favorable for targeted drug delivery. 24 The saturation magnetization (M s ) of Strep-CS-MNP at ±11,700 O e was measured as 38.4 emu/g, whereas the M s value for the magnetic nanoparticle was 80.1 emu/g. However, the M s for Strep-CS-MNP was less than that for the magnetic nanoparticle. The decrease in Ms for Strep-CS-MNP could be due to the polymer coating and the exchange of electrons between the surface of Fe atoms and the polymer, 20, 22, 25 indicating that the magnetic nanoparticles were coated with the polymer.
scanning electron microscopy analysis Figure 6 shows the surface morphology of the MNP nanoparticles and the Strep-CS-MNP nanocomposite observed by scanning electron microscopy. Figure 6 shows that the MNP and the Strep-CS-MNP nanocomposite have strong agglomeration due to van der Waals forces between the particles. The degree of agglomeration was decreased in Strep-CS-MNP due to coating of the MNP nanoparticles by the chitosan polymer.
In vitro release of streptomycin from strep-cs-MNP
The release profiles for streptomycin from the Strep-CS-MNP nanocomposite using 0.01 M phosphate-buffered saline and release of streptomycin from the physical mixture of streptomycin, chitosan and magnetic nanoparticles are shown in Figure 7 . As can be seen from the inset of this figure, the free streptomycin (physical mixture) was released rapidly into phosphate-buffered saline, with complete release taking place within 20 minutes. The release rate of streptomycin from the nanocomposite is obviously lower than that of the free mixture, indicating that the nanocomposite is a potential controlled-release drug delivery system. It is worth noting that the rapid release during the first 20 minutes is due to the burst effect. A slower release was observed from 25 to 350 minutes, and the amount of streptomycin released from the nanocomposite at 350 minutes was 100%.
release kinetics of streptomycin from strep-cs-MNP In order to obtain more information on the release behavior of streptomycin from the Strep-CS-MNP nanocomposite, a pseudo-first order model (Equation 2), 26 a pseudo-second order model (Equation 3) , 27 the Higuchi model (Equation 4), 28 the Hixson-Crowell model (Equation 5), 28 and the Korsmeyer-Peppas model (Equation 6) 28 were chosen as follows:
ln (q e − q t ) = ln q e − kt (2) t/q t = 1/k q e 2 + t/q e (3)
where q e and q t are the equilibrium release amounts and the release amounts at any time (t), respectively, M o and M t is the initial amount and the amount of the drug in the nanocomposite at time t, respectively. Based on the five models, the fitted results of the streptomycin release profiles are given in Figure 8 and Table 1 . It can be seen that the pseudo-second order model can be better fitted to the data for streptomycin release behavior than the other models. Figure 8B shows the plots of t/q t versus t for the release of streptomycin. The correlation coefficient (R 2 ) value was 0.9863, compared with 0.8772, 0.9280, 0.9394, and 0.9235 for the pseudo-first order model, the Higuchi model, the Hixson-Crowell model, and the Korsmeyer-Peppas model, respectively.
In vitro antibacterial activity of strep-cs-MNP
In the present study, the antibacterial activity of the assynthesized Strep-CS-MNP was determined against a strain of MRSA using the agar diffusion method as described previously. Strep-CS-MNP showed antimicrobial activity against MRSA, as indicated by the clear inhibition zone shown in Figure 9 . The diameters of the inhibition zone for Strep-CS-MNP were 17 mm for B and 21 mm for C as compared to 32 mm for free streptomycin (A), which indicates that the as-synthesized Strep-CS-MNP showed enhanced antibacterial activity.
As a field of research with promising and vast applications in pharmaceutical and biomedical development, nanoantimicrobial agents are being developed based on several metal and metal oxide nanoparticles, including silver, gold, zinc, and copper, 2, 22, [29] [30] [31] despite concerns about the toxicity of their metal content, such as accumulation in the body and other cytotoxic and genotoxic effects as compared with their antimicrobial benefits. 32, 33 In addition to
International Journal of Nanomedicine 2014:9
submit your manuscript | www.dovepress.com
Dovepress
555
Novel streptomycin-chitosan-magnetic nanoantibiotic Log (% release) Log (t) Figure 8 Fitting of data for streptomycin release from the streptomycin-loaded chitosan-magnetic nanoparticle nanocomposite for different kinetic models at ph 7.4.
the research efforts being devoted to develop chemically modified new generations and more stable derivatives of aminoglycosides in order to improve their clinical advantages and to overcome the escalating antimicrobial resistance, nanoparticle-based antibiotics, commonly known as nanoantibiotics or nanobiotics (the terms are used interchangeably) were very recently introduced and represent a major breakthrough in nanomedicine, 34, 35 although the literature thus far contains very few reports on antibiotic-loaded nanoparticles.
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Conclusion and future perspectives
Magnetic iron oxide nanoparticles were prepared with chitosan by incorporation methods, and characterized using FTIR spectroscopy, X-ray diffraction, thermogravimetric analysis, and vibrating sample magnetometry. Streptomycin was incorporated into the nanoparticles. Vibrating sample magnetometry studies showed the supermagnetic properties of the magnetic nanoparticles. The streptomycin loading was 4.2%. Drug release was also studied, and the total release equilibrium of streptomycin from Strep -CS-MNP was 100% in 350 minutes. The drug release profiles showed initially rapid release, which became slower as time progressed. The best fitting of mathematical model was the pseudo-second order model. To the authors' knowledge, this is the first report on the synthesis of nanoparticles loaded with streptomycin as a prototype aminoglycoside antibiotic and would pave the way for further promising research. Further investigation of the activity of the Strep-CS-MNP nanocomposites against other microorganisms including Mycobacterium tuberculosis and in vivo studies to elucidate drug delivery, stability against bacterial resistance, and the toxicity and side effects of Strep -CS-MNP would provide opportunities for future advances in nanobiotics and nanomedicine in the clinical setting.
The widespread emergence of microbial resistance to several classes of antimicrobial agents raises more concerns in health care and public health, perhaps heralding a resurgence of bacterial outbreaks caused by microorganisms with the potential to cause fatal infections in humans and animals. Antimicrobialresistant microorganisms require more extensive chemotherapy, involving drug therapy over an extended period, which may often end unsuccessfully, and is more expensive (billions of dollars) than treatment for antimicrobial-susceptible microrganisms. The pros and cons of the potential applications of nanoantibiotics as potential treatment options in a post-antibiotic era to control infectious diseases and offset the overwhelming microbial resistance should be fully addressed and evaluated. The clinical ineffectiveness and effectiveness of several commonly used antibiotics (such as β-lactams, aminoglycosides, and macrolides, as well as antifungal antibiotics such as polyenes) mandate the expedited requirement for improvements in drug design, discovery, and delivery. In addition, further studies on the antimicrobial spectra of novel Strep-CS-MNP nanoparticles against M. tuberculosis and related microorganisms could offer new antimycobacterial and antimicrobial alternatives in the treatment of infectious diseases.
Development of new antimicrobial agents usually takes a few years to reach clinical application; however, nanomedicine provides a rapid tool to enhance and restore the antimicrobial activity of old and current antibiotics that are affected by the multiple drug resistance arsenal of pathogens. Future research in the nanoantibiotic field should be expanded and devoted to address different aspects regarding delivery, safety, and possible toxicity of such novel nanoscale antimicrobial agents.
